Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07160582 · ClinicalTrials.gov registry record · NA
Cognitive-Motor Training for AD/ADRD Prevention
A NA study, sponsored by University of Illinois at Chicago.
- Not yet
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT07160582 is a NA study that has not yet begun recruiting, run by University of Illinois at Chicago. The registered enrollment target is 46 participants.
The verdict
NCT07160582, a NA study, has not yet begun recruiting, sponsored by University of Illinois at Chicago.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
Alzheimer's disease and related dementias (AD/ADRD) greatly affect memory and daily activities in older adults. Mild Cognitive Impairment (MCI) is an early stage of dementia, affecting about 17% of older adults. People with MCI often show problems with gait and balance, which doubles their risk of falling compared to cognitively healthy peers. Falls can cause injuries, increase sedentary behavior, and reduce physical activity. This decline in activity can also speed up the progression from MCI to dementia. Exercise can help older adults make healthy lifestyle changes; however, most of the existing exercise programs focus mainly on physical movement rather than cognitive function. Therefore, the investigators developed a new program that uses computer vision and a cloud-based system to provide more scalable, engaging, and personalized cognitive-motor training for OAwMCI. The purpose of this study is to investigate the short- and long-term effects of a novel CogXergaming training (CXT) paradigm for improving the cognitive-motor function, physical activity, falls efficacy, and quality of life.
Interventions
- BEHAVIORAL Novel CogXergaming Training
- BEHAVIORAL Exercise and Education Training Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07160582
The ClinicalTrials.gov registry entry for NCT07160582 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Novel CogXergaming Training is the first listed.
NCT07160582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07160582 about?
NCT07160582 is a clinical study titled "Cognitive-Motor Training for AD/ADRD Prevention". Alzheimer's disease and related dementias (AD/ADRD) greatly affect memory and daily activities in older adults. Mild Cognitive Impairment (MCI) is an early stage of dementia, affecting about 17% of older adults. People with MCI often show problems with gait and balance, which doubles their risk of f...
What is the current status of trial NCT07160582?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2026-05-01. Estimated completion is 2027-09-01.
What interventions are being tested in trial NCT07160582?
The interventions under investigation include: Novel CogXergaming Training (BEHAVIORAL), Exercise and Education Training Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT07160582?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.